Slingshot Insights | Imgn Overview

IMGN Overview

Upcoming Projects (IMGN)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (IMGN)

A Second Look at the potential ImmunoGen's, Elahere (mirvetuximab soravtansine-gynx) in folate receptor alpha(FRα)-positive cancers and the results from the Phase 3 MIRASOL Confirmatory trial presented at ASCO.
Ticker: IMGN
Executed On: Jun 16, 2023 at 03:00 PM EDT
A look at the potential ImmunoGen's, Elahere (mirvetuximab soravtansine-gynx) in folate receptor alpha(FRα)-positive cancers and the results from the Phase 3 MIRASOL Confirmatory trial presented at ASCO.
Ticker: IMGN
Executed On: Jun 09, 2023 at 06:00 PM EDT
A Third Take: Examining the potential of Immunogen's ELAHERE (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer.
Ticker: IMGN
Executed On: Mar 02, 2023 at 10:00 AM EST
A Second View: Examining the potential of Immunogen's ELAHERE (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer.
Ticker: IMGN
Executed On: Mar 01, 2023 at 03:00 PM EST
Examining the potential of Immunogen's ELAHERE (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer.
Ticker: IMGN
Executed On: Feb 23, 2023 at 03:00 PM EST
A second look at the P1 data presented at ESMO for ubamatamab, a CD3-targeting bispecific antibody under investigation for recurrent ovarian cancer
Tickers: REGN, AZN, CLVS, IMGN, GSK, RHHBY
Executed On: Sep 29, 2022 at 05:15 PM EDT

Upcoming & Overdue Catalysts (IMGN)

Don’t see a catalyst related to the company you care about? Create your own!

Strategic Initiatives (IMGN)

Don’t see a strategic initiative related to the company you care about? Create your own!